Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CRBN | Q96SW2 | 10/20 | 0.59 |
| ▸ | BRD4 | O60885 | 9/20 | 0.57 |
| ▸ | TNF | P01375 | 1/20 | 0.55 |
| ▸ | IL1B | P01584 | 1/20 | 0.55 |
| ▸ | IKZF1 | Q13422 | 1/20 | 0.55 |
| ▸ | DDB1 | Q16531 | 1/20 | 0.55 |
| ▸ | IKZF3 | Q9UKT9 | 1/20 | 0.55 |
| ▸ | MAP1LC3B | Q9GZQ8 | 4/20 | 0.53 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20362334 | 1.00 | CRBN (0.59) | CRBNBRD4TNFIL1BIKZF1 | |
| SCHEMBL22464808 | 1.00 | CRBN (0.59) | CRBNBRD4TNFIL1BIKZF1 | |
| SCHEMBL29137874 | 1.00 | CRBN (0.59) | CRBNBRD4TNFIL1BIKZF1 | |
| SCHEMBL22464461 | 0.99 | CRBN (0.60) | CRBNBRD4TNFIL1BIKZF1 | |
| SCHEMBL464519 | 0.97 | CRBN (0.60) | CRBNBRD4TNFIL1BIKZF1 | |
| SCHEMBL26323874 | 0.96 | CRBN (0.63) | CRBNBRD4TNFIL1BIKZF1 | |
| SCHEMBL26317744 | 0.96 | CRBN (0.63) | CRBNBRD4TNFIL1BIKZF1 | |
| SCHEMBL26321035 | 0.96 | CRBN (0.63) | CRBNBRD4TNFIL1BIKZF1 | |
| SCHEMBL26323878 | 0.96 | CRBN (0.63) | CRBNBRD4TNFIL1BIKZF1 | |
| SCHEMBL26321021 | 0.95 | CRBN (0.64) | CRBNBRD4TNFIL1BIKZF1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20210253564-A1 | Pyridazine Derivatives as SMARCA2/4 Degraders | AURIGENE DISCOVERY TECHNOLOGIES LIMITED (IN) | 2021-08-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210253564-A1 | Pyridazine Derivatives as SMARCA2/4 Degraders | SMARCC1, SMARCC2, SMARCA2 | CRBN 393/4885BRD4 75/4885TNF 4435/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.